ShEEP Request for CTL ImmunoSpot S6 Universal Analyzer
ShEEP Request for CTL ImmunoSpot S6 Universal Analyzer
批准号:
9795713
负责人:
Chinthalapally V. Rao
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-01-01 至 2019-09-30
关键词:
Alzheimer&aposs DiseaseAntineoplastic AgentsAppointmentAreaArthritisB-LymphocytesBiological AssayCancer CenterCarcinomaCell CommunicationCellsCellular biologyChronicChronic DiseaseCitiesColorCommunitiesComplexCost of IllnessCytotoxic T-LymphocytesDefense MechanismsDegenerative polyarthritisDetectionDevelopmentDiseaseDisease ProgressionFlow CytometryFundingFutureGrantHealth SciencesHeart DiseasesHepatitisHeterogeneityImage AnalysisImmuneImmunologic MarkersImmunologic MonitoringImmunologicsImmunologyImmunooncologyInfectionInfiltrationInflammationInflammatoryInflammatory Bowel DiseasesInstitutionLeadershipMaintenanceMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMeasuresMediatingMedical centerMethodologyMicroscopicMinorMolecularMonitorNatureNon-Insulin-Dependent Diabetes MellitusObesityOklahomaPancreatitisPathologicPeer ReviewPerformancePeripheral Blood Mononuclear CellPlayPreventiveReaderResearchResearch ActivityResearch PersonnelResourcesRoleSample SizeScientistSheepSurveysT-LymphocyteTechnologyTimeTissuesUnited StatesUnited States National Institutes of HealthUniversitiesVeteransantigen-specific T cellsbasecareercell typecellular targetingcytokinedesigndrug developmentenzyme linked immunospot assayflexibilityinstrumentinterestmacrophageparticlepreventranpirnaseresearch facilitytooltumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We are requesting funds to purchase a CTL ImmunoSpot® S6 Universal Analyzer. This instrument
allows investigators primarily to perform multi-color ELISPOT analysis along with other cell-
based applications. Currently, neither the research facility at the Oklahoma City VA Medical
Center (OKC VAMC) nor the affiliated University of Oklahoma Health Sciences Center has
this high-end ELISPOT analyzer. It is well known that immune cells play a critical role in many
diseases including cancer. It is now becoming evident that changes in immune cell heterogeneity
potentially impacts either positively or negatively on the disease progression. However, in the past
only limited technology allowed investigators to study heterogeneity of immune cells, immune
cells interaction with other cell types and their molecular impact in the tissue microenvironment
and more so, immunological markers interface in tissue microenvironment and systemically.
Immune monitoring is complex and better understanding requires multiplexing. CTL
ImmunoSpot® S6 Universal Analyzer permit multicolor T and B cell fluorospot analysis,
live/dead PBMC counting, and much more. This is an attractive alternative to flow cytometry
analysis. CTL ImmunoSpot® S6 Universal Analyzer also allows investigators for other
applications at the microscopic (single cells and subcellular particles) as well as the macroscopic
level (colonies and Plaques). The primary field of application for CTL ImmunoSpot® S6 Universal
Analyzer has been multi-color ELISPOT analysis. CTL employs a technology specifically
designed to avoid excitation cross-contamination, enabling the accurate detection of up to eight
analyte co-expressing cells, including polyfunctional T cells. In addition, image analysis-based
multi-parameter analysis of cells with CTL ImmunoSpot® S6 Universal Analyzer can be useful
with both adherent or non-adherent cells alike, and the sample size for analysis can be as low as
one cell.
A survey of all VA researchers at OKC VAMC showed over 80% of the researchers are potentially
interested to use CTL ImmunoSpot® S6 Universal Analyzer to study the modulation of antigen-
specific T cell induction and activation in their research. This instrument will be used by six major
users who have VA Merit grants funded or pending. We also anticipate that researchers at other
VA centers will use this instrument.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting GCNT3 for Pancreatic Cancer
-
批准号:10260098
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Chinthalapally V. Rao
-
依托单位:
Targeting GCNT3 for Pancreatic Cancer
-
批准号:10512747
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Chinthalapally V. Rao
-
依托单位:
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTIO
-
批准号:10269136
-
项目类别:
-
资助金额:$78.52万
-
财政年份:2020
-
负责人:Chinthalapally V. Rao
-
依托单位:
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.
-
批准号:10674662
-
项目类别:
-
资助金额:$24.41万
-
财政年份:2020
-
负责人:Chinthalapally V. Rao
-
依托单位:
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.
-
批准号:10269139
-
项目类别:
-
资助金额:$66.63万
-
财政年份:2020
-
负责人:Chinthalapally V. Rao
-
依托单位:
Safer Approaches to CRC Chemoprevention
-
批准号:10063852
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2016
-
负责人:Chinthalapally V. Rao
-
依托单位:
Safer Approaches to CRC Chemoprevention
-
批准号:10260715
-
项目类别:
-
资助金额:$21.75万
-
财政年份:2016
-
负责人:Chinthalapally V. Rao
-
依托单位:
Safer Approaches to CRC Chemoprevention
-
批准号:9261808
-
项目类别:
-
资助金额:$45.86万
-
财政年份:2016
-
负责人:Chinthalapally V. Rao
-
依托单位:
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS
-
批准号:6815750
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2004
-
负责人:Chinthalapally V. Rao
-
依托单位:
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS
-
批准号:6952292
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2004
-
负责人:Chinthalapally V. Rao
-
依托单位:
PREVENTION OF COLORECTAL CANCER BY iNOS AND COX-2 SELECTIVE INHIBITORS
-
批准号:7256443
-
项目类别:
-
资助金额:$28.48万
-
财政年份:2004
-
负责人:Chinthalapally V. Rao
-
依托单位:
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS
-
批准号:7113809
-
项目类别:
-
资助金额:$29.33万
-
财政年份:2004
-
负责人:Chinthalapally V. Rao
-
依托单位:
PREVENTION OF COLORECTAL CANCER BY iNOS AND COX-2 SELECTIVE INHIBITORS
-
批准号:7475719
-
项目类别:
-
资助金额:$28.48万
-
财政年份:2004
-
负责人:Chinthalapally V. Rao
-
依托单位:
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER
-
批准号:7026972
-
项目类别:
-
资助金额:$28.65万
-
财政年份:2002
-
负责人:Chinthalapally V. Rao
-
依托单位:
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER
-
批准号:6622903
-
项目类别:
-
资助金额:$35.82万
-
财政年份:2002
-
负责人:Chinthalapally V. Rao
-
依托单位:
HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal Cancer
-
批准号:8244563
-
项目类别:
-
资助金额:$28.91万
-
财政年份:2002
-
负责人:Chinthalapally V. Rao
-
依托单位:
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER
-
批准号:6949821
-
项目类别:
-
资助金额:$26.37万
-
财政年份:2002
-
负责人:Chinthalapally V. Rao
-
依托单位:
HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal Cancer
-
批准号:7992104
-
项目类别:
-
资助金额:$29.81万
-
财政年份:2002
-
负责人:Chinthalapally V. Rao
-
依托单位:
HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal Cancer
-
批准号:8624661
-
项目类别:
-
资助金额:$28.05万
-
财政年份:2002
-
负责人:Chinthalapally V. Rao
-
依托单位:
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER
-
批准号:6864445
-
项目类别:
-
资助金额:$32.6万
-
财政年份:2002
-
负责人:Chinthalapally V. Rao
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: